Skip to content
Home/Companies/Biotech/Depth Charge Therapeutics

Depth Charge Therapeutics

Biotech·Ireland·Active·5yr hold
Entry
2021
Hold
5yr
Status
Active

Who owns Depth Charge Therapeutics?

Depth Charge Therapeutics is an Irish Biotech company, currently owned by AdBio Partners since 2021.

Hand-verified · updated 2026-05-24

Open JSON · CC-BY
AdBio Partners
Investor
AdBio Partners
AFB Fund II · 2021 · VC

Key facts

HQIreland
SectorBiotech
StatusActive

More from AFB Fund II

Other portfolio companies in the same fund.

Orikine Bio
Active
BiotechSpain· 2026
AndzonBio2
AndzonBio2
Active
BiotechFrance· 2025
Cephagenix
Cephagenix
Active
BiotechDenmark· 2025
EvlaBio
Active
BiotechGermany· 2025
AndzonBio1
AndzonBio1
Active
BiotechFrance· 2024
Anoat Therapeutics
Active
BiotechFrance· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Depth Charge Therapeutics?

Depth Charge Therapeutics is currently owned by AdBio Partners, through AFB Fund II, since 2021.

When did AdBio Partners acquire Depth Charge Therapeutics?

AdBio Partners acquired Depth Charge Therapeutics in 2021.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue